Financial Snapshot

Revenue
$34.68M
TTM
Gross Margin
58.88%
TTM
Net Earnings
-$5.481M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
150.75%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$15.98M
Q3 2024
Cash
Q3 2024
P/E
-57.46
Nov 29, 2024 EST
Free Cash Flow
$1.332M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $31.64M $21.25M $21.83M $40.00K $960.0K $0.00 $0.00
YoY Change 48.9% -2.66% 54480.0% -95.83%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $31.64M $21.25M $21.83M $40.00K $960.0K $0.00 $0.00
Cost Of Revenue $10.58M $6.933M $2.623M $290.0K $450.0K
Gross Profit $21.06M $14.32M $19.21M -$250.0K $510.0K
Gross Profit Margin 66.56% 67.38% 87.99% -625.0% 53.13%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $18.93M $18.58M $14.47M $12.76M $7.550M $4.690M $3.220M
YoY Change 1.88% 28.43% 13.39% 69.01% 60.98% 45.65%
% of Gross Profit 89.89% 129.78% 75.32% 1480.39%
Research & Development $3.322M $3.996M $6.235M $14.10M $11.56M $5.630M $3.930M
YoY Change -16.87% -35.91% -55.78% 21.97% 105.33% 43.26%
% of Gross Profit 15.77% 27.91% 32.46% 2266.67%
Depreciation & Amortization $44.00K $66.00K $462.0K $650.0K $450.0K $60.00K $10.00K
YoY Change -33.33% -85.71% -28.92% 44.44% 650.0% 500.0%
% of Gross Profit 0.21% 0.46% 2.41% 88.24%
Operating Expenses $22.25M $22.58M $20.70M $26.86M $19.11M $10.32M $7.150M
YoY Change -1.44% 9.05% -22.92% 40.55% 85.17% 44.34%
Operating Profit -$1.192M -$8.260M -$1.495M -$27.11M -$18.60M
YoY Change -85.57% 452.51% -94.49% 45.75%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $1.060M $955.0K -$1.006M -$860.0K $280.0K $160.0K $40.00K
YoY Change 10.99% -194.93% 16.98% -407.14% 75.0% 300.0%
% of Operating Profit
Other Income/Expense, Net $503.0K -$761.0K -$1.006M $0.00 -$2.580M -$40.00K
YoY Change -166.1% -24.35% 6350.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$689.0K -$9.021M -$1.955M -$27.97M -$18.32M -$12.74M -$7.160M
YoY Change -92.36% 361.43% -93.01% 52.67% 43.8% 77.93%
Income Tax $247.0K $0.00 $0.00
% Of Pretax Income
Net Earnings -$936.0K -$9.021M -$1.955M -$27.97M -$18.32M -$12.74M -$7.160M
YoY Change -89.62% 361.43% -93.01% 52.67% 43.8% 77.93%
Net Earnings / Revenue -2.96% -42.45% -8.95% -69925.0% -1908.33%
Basic Earnings Per Share -$0.04 -$0.36 -$0.08 -$1.33
Diluted Earnings Per Share -$0.04 -$0.36 -$77.56K -$1.331M -$1.032M -$723.5K -$438.7K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $21.39M $16.31M $14.41M $21.30M $12.07M $26.74M $13.16M
YoY Change 31.17% 13.18% -32.37% 76.47% -54.86% 103.19%
Cash & Equivalents $21.39M $16.31M $14.41M $21.30M $12.07M $26.74M $13.16M
Short-Term Investments
Other Short-Term Assets $1.129M $1.290M $3.177M $2.120M $2.090M $770.0K $140.0K
YoY Change -12.48% -59.4% 49.86% 1.44% 171.43% 450.0%
Inventory $911.0K $557.0K $550.0K $1.240M $380.0K
Prepaid Expenses
Receivables $3.411M $1.852M $5.471M $50.00K $470.0K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $26.84M $20.00M $23.60M $24.70M $15.01M $27.50M $13.29M
YoY Change 34.17% -15.25% -4.44% 64.56% -45.42% 106.92%
Property, Plant & Equipment $150.0K $260.0K $219.0K $1.000M $1.280M $770.0K $120.0K
YoY Change -42.31% 18.72% -78.1% -21.88% 66.23% 541.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.00K $12.00K $21.00K $40.00K $60.00K $50.00K $30.00K
YoY Change 0.0% -42.86% -47.5% -33.33% 20.0% 66.67%
Total Long-Term Assets $4.901M $5.026M $3.861M $1.620M $2.060M $830.0K $150.0K
YoY Change -2.49% 30.17% 138.33% -21.36% 148.19% 453.33%
Total Assets $31.74M $25.03M $27.47M $26.32M $17.07M $28.33M $13.44M
YoY Change
Accounts Payable $1.848M $1.691M $1.774M $2.340M $580.0K $1.420M $540.0K
YoY Change 9.28% -4.68% -24.19% 303.45% -59.15% 162.96%
Accrued Expenses $9.013M $3.737M $1.366M $1.170M $1.390M $600.0K $250.0K
YoY Change 141.18% 173.57% 16.75% -15.83% 131.67% 140.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.380M $1.033M $1.418M $280.0K
YoY Change 420.81% -27.15% 406.43%
Total Short-Term Liabilities $16.24M $6.461M $4.558M $3.790M $1.960M $2.020M $790.0K
YoY Change 151.37% 41.75% 20.26% 93.37% -2.97% 155.7%
Long-Term Debt $0.00 $5.384M $5.262M $6.760M $4.540M $0.00 $0.00
YoY Change -100.0% 2.32% -22.16% 48.9%
Other Long-Term Liabilities $22.00K $107.0K $15.00K $100.0K $20.00K $0.00 $520.0K
YoY Change -79.44% 613.33% -85.0% 400.0% -100.0%
Total Long-Term Liabilities $22.00K $5.491M $5.277M $6.860M $4.560M $0.00 $520.0K
YoY Change -99.6% 4.06% -23.08% 50.44% -100.0%
Total Liabilities $16.26M $11.95M $9.835M $10.66M $6.520M $2.020M $1.310M
YoY Change 36.07% 21.53% -7.74% 63.5% 222.77% 54.2%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 25.65M 25.15M shares 25.21M shares 21.01M shares
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $314.94 Million

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 30 full-time employees. The company went IPO on 2018-11-09. The firm is focused on developing and commercializing treatments for rare diseases. The firm has five commercial rare disease products: ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The firm has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. ALKINDI SPRINKLE is a granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with adrenal insufficiency. PKU GOLIKE is a next generation medical formula product engineered with the patent protected, pharmaceutical grade Physiomimic technology for the dietary management of phenylketonuria (PKU) under medical supervision. Carglumic Acid is used for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is developed for the treatment of homocystinuria.

Industry: Pharmaceutical Preparations Peers: 9 METERS BIOPHARMA, INC. NRX Pharmaceuticals, Inc. Enliven Therapeutics, Inc. JOHNSON & JOHNSON Journey Medical Corp OPIANT PHARMACEUTICALS, INC. Mystic Holdings Inc./NV Odonate Therapeutics, Inc.